Show notes
Breakthroughs in CRISPR and human germline editing aremoving genetic engineering from curing rare diseases to rewriting the inheritedDNA of future generations. In this investigative documentary, we examine themulti-billion-dollar race to commercialize human genetics—and ask what happenswhen biological upgrades are locked behind a corporate paywall.
As bioethics committees slowly reconsider bans on heritable germlineediting, the boundary between curing fatal disease and commercial traitenhancement is beginning to blur. When polygenic embryo selection merges withmulti-million-dollar medicine…
Website: podcasters.spotify.com

